GlassScriptPhysician profile
William B Faircloth
NPI 1932100112
$5,755.08
in general payments reported to CMS, 2019-2025
35 companies · $28.40 in 2025
The $28.40 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $4,245 · 2021: $509 · 2022: $329 · 2023: $231 · 2024: $15.29 · 2025: $28.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $274.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Precision Spine, INC. | $2,993.21 | 2020-2021 | |
| Globus Medical, INC. | $1,085.38 | 2020 | |
| Sk Life Science, INC. | $233.26 | 2020-2023 | |
| Tanabe Pharma America, INC. | $165.11 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $155.65 | 2019-2023 | Nuplazid |
| Adamas Pharmaceuticals, INC. | $155.56 | 2019-2021 | |
| Abbvie INC. | $111.01 | 2019-2025 | |
| Acorda Therapeutics, INC | $64.06 | 2022 | |
| Novartis Pharmaceuticals Corporation | $61.50 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $61.04 | 2019-2023 | Soliris |
| Ucb, INC. | $60.83 | 2019-2022 | |
| Biogen, INC. | $51.08 | 2019-2022 | |
| Kyowa Kirin, INC. | $45.88 | 2020-2021 | |
| Emd Serono, INC. | $44.40 | 2020-2021 | |
| Medtronic, INC. | $42.30 | 2021-2024 | Intellis Adaptivestim |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $36.53 | 2020 | |
| Arbor Pharmaceuticals, INC. | $34.67 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $32.95 | 2023 | Xeomin |
| Biohaven Pharmaceutical Holding Company LTD. | $31.23 | 2022 | |
| Misonix INC | $30.02 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $26.16 | 2019 | |
| Lundbeck LLC | $23.82 | 2020 | |
| Alnylam Pharmaceuticals INC. | $22.76 | 2023 | Amvuttra |
| Catalyst Pharmaceuticals, INC. | $21.32 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.61 | 2022 | |
| Scilex Pharmaceuticals INC. | $17.63 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.45 | 2022 | |
| Neurocrine Biosciences, INC. | $16.64 | 2019 | |
| Merz North America, INC. | $14.88 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.75 | 2022 | |
| Ethicon US, LLC | $14.52 | 2021 | |
| Currax Pharmaceuticals LLC | $14.25 | 2020 | |
| Upsher-Smith Laboratories LLC | $11.99 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.84 | 2019 | |
| Lilly USA, LLC | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Faircloth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.